TrialEpilepsia open2026

A first in disease trial of the safety, tolerability, and anti-seizure effects of ES-481 in drug-resistant epilepsy.

Emma C Foster et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.